Role of the dengue vaccine TAK-003 in an outbreak response: Modeling the Sri Lanka experience.

ABSTRACT:

Background

Outbreaks of dengue can overburden hospital systems, drastically reducing capacity for other care. The 2017 dengue serotype 2 (DENV-2) outbreak in Sri Lanka coincided with vaccination in an ongoing phase 3 efficacy trial of a tetravalent dengue vaccine, TAK-003 (NCT02747927). Here, we present data on the efficacy of TAK-003 following two doses of the vaccine administered 3 months apart in participants aged 4-16 years in Sri Lanka. In addition, we have used the 2017 outbreak dynamics to model the potential impact of TAK-003 on virologically confirmed dengue (VCD) cases and hospitalizations during an outbreak situation.

Methodology/principal findings

Modeling was performed using an age-structured, host-vector, spatial and stochastic transmission model, assuming 65%

SUBMITTER: Fernando L 

PROVIDER: S-EPMC11419351 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature